ClinicalTrials.gg
RecruitingNCT07259980Updated Apr 9, 2026

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

An observational study in Amyotrophic Lateral Sclerosis, sponsored by Biogen. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Biogen · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
125
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Amyotrophic Lateral Sclerosis by Biogen — 2 open to participants now, 4 under way, 1 of them phase 3. Amyotrophic Lateral Sclerosis · Biogen.

Started
2026
with 1 other
Observational
2 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Amyotrophic Lateral Sclerosis by Biogen, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 9th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

2 of the 11 studies in Amyotrophic Lateral Sclerosis by Biogen are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Amyotrophic Lateral Sclerosis by Biogen, or all of them as a file.
02

Study summary

In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for participant with a certain type of amyotrophic lateral sclerosis, also known as ALS. This type is in participant who have a mutation in the superoxide dismutase 1 gene, also known as SOD-1.

This is known as an "observational" study, which collects health information about study participants without changing their medical care. Participants for this study will be found using 2 different groups of study research centers that help provide clinical care for participant with ALS. These groups are in Europe and the United States and are called:

  • the Precision-ALS programme
  • the ALS/Motor Neuron Disease (MND) Natural History Consortium (NHC)

The main goal of this study is to collect safety information in participants with SOD-1 ALS who were in either of the groups.

The main question researchers want to answer in this study is:

  • What are the characteristics of the participants in this study?
  • How many participants had serious adverse events (SAEs), including ones that affect the brain, spinal cord, or nerves?

An adverse event is a health problem that may or may not be caused by a drug during the study. An adverse event is considered serious when it results in death, is life-threatening, causes lasting problems, or requires hospital care.

Researchers will also learn more about:

  • How many participants develop other health conditions or become pregnant, including how the pregnancy turned out
  • Why and when participants stopped treatment

This study will be done as follows:

  • Participants will be screened to check if they can join the study.
  • Data from the participants' regular visits to their clinic will be collected based on which study research center they are in.
  • Each participant will be in the study until they decide to leave or until death. Currently, the study is planned to last at least 7 years.
Read the detailed description

The primary objectives of this study are to describe demographic and clinical characteristics of participants with superoxide dismutase 1-amyotropic lateral sclerosis (SOD1-ALS); to describe the frequency of SAEs among participants with SOD1-ALS, including serious neurologic events previously reported in clinical trial participants (e.g., myelitis, radiculitis, aseptic meningitis, increased intracranial pressure, and/or papilloedema).

The secondary objectives of this study are to describe the frequency of new comorbid conditions, pregnancy and pregnancy outcome among participants with SOD1-ALS; to describe the frequency of treatment discontinuation among participants with SOD1-ALS treated with tofersen.

NHC registry has started the data collection while the Treatment Research Initiative to Cure ALS (TRICALS) is yet to start.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with SOD1-ALS enrolled in TRICALS network's Precision-ALS programme with data from participating clinical centers across multiple European countries or at ALS/MND NHC with data from participating clinical centers in the United States (tofersen users and tofersen non-users).

Eligibility criteria

Key Inclusion Criteria:

  • Participants with an ALS diagnosis and a confirmed SOD1 mutation from contributing registry networks will be considered for inclusion in the study.

Key Exclusion Criteria:

  • Data collected while a person with SOD1-ALS is participating in an interventional clinical trial (with tofersen or any other medicinal product) will be excluded.

NOTE: Other protocol- defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
125 participants (estimated)
Target follow-up
7 Years
Patient registry
Yes

Groups and cohorts

  • Tofersen

    Data for participants with SOD1-ALS will be collected via ALS disease registries, the TRICALS network's Precision-ALS programme and ALS/MND NHC.

    Drug: Tofersen

Interventions

  • Administered as specified in the treatment arm.

    Also known as: BIIB067, Qalsody

06

What researchers measure

Primary outcomes

  1. Baseline Demographic: Age

    Time frame: At Baseline

  2. Baseline Demographic: Participant Sex

    Time frame: At Baseline

  3. Baseline Demographic: Race/Ethnicity

    Time frame: At Baseline

  4. Baseline Demographic: Weight

    Time frame: At Baseline

  5. Baseline Demographic: Height

    Time frame: At Baseline

  6. Baseline Demographic: Body Mass Index (BMI)

    Time frame: At Baseline

  7. Baseline Demographic: Family History of Amyotrophic Lateral Sclerosis (ALS)

    Time frame: At Baseline

  8. Clinical Characteristics: Age at Diagnosis and Symptom Onset

    Time frame: At Baseline

  9. Clinical Characteristics: Revised El Escorial Classification

    Time frame: At Baseline

  10. Clinical Characteristics: Classification of SOD1-ALS Clinical Phenotypes

    Time frame: At Baseline

  11. Clinical Characteristics: SOD1 Mutation Type

    Time frame: At Baseline

  12. Clinical Characteristics: Medical History

    Time frame: At Baseline

  13. Clinical Characteristics: Concomitant Medications

    Time frame: At Baseline

  14. Clinical Characteristics: Disease History

    Time frame: At Baseline

  15. Clinical Characteristics: Pregnancy Status

    Time frame: At Baseline

  16. Number of Participants With Serious Adverse Events

    Time frame: Up to 7 years

Secondary outcomes

  1. Number of Participants With New Comorbid Conditions

    Time frame: Up to 7 years

  2. Number of Participants With Pregnancy and Pregnancy Outcomes

    Time frame: Up to 7 years

  3. Number of Participants With Reported Treatment Discontinuation

    Time frame: Up to 7 years

  4. Number of Participants With Reported Reasons for Treatment Discontinuation

    Time frame: Up to 7 years

07

Study locations

1 of 1 sites recruiting
  • Mass General Hospital -MGH
    Boston, Massachusetts 02114, United States
    Recruiting
    • · Contact617-643-2935
    • Alex Sherman · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2033, 95 months after the start.

Of 138 observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 114. This study's planned 95 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2025
First posted
Dec 2, 2025
StartActual
Jan 2, 2026
Primary completionEst.
Dec 30, 2033
CompletionEst.
Dec 30, 2033
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07259980
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Jan 2, 2026
Primary completion
Dec 30, 2033 (estimated)
Completion
Dec 30, 2033 (estimated)
Last update
Apr 9, 2026

Study contacts

Study US Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
866-633-4636
Global Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion